Jiménez-Ballvé A, García García-Esquinas M, Salsidua-Arroyo O, Serrano-Palacio A, García-Sáenz J A, Ortega Candil A, Fuentes Ferrer M E, Rodríguez Rey C, Román-Santamaría J M, Moreno F, Carreras-Delgado J L
Servicio de Medicina Nuclear, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria Hospital Clínico San Carlos, Madrid, España.
Servicio de Medicina Nuclear, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria Hospital Clínico San Carlos, Madrid, España.
Rev Esp Med Nucl Imagen Mol. 2016 Nov-Dec;35(6):365-372. doi: 10.1016/j.remn.2016.01.007.
To determine whether metabolic tumour volume (MTV) and total lesion glycolysis (TLG) are able to predict recurrence risk in locally advanced breast cancer (LABC) patients.
Retrospective study of LABC patients who undertook neoadjuvant, local and adjuvant treatment and follow up. A F-FDG PET/CT study for initial staging was performed analysing in this study different metabolic parameters (MTV, TLG, SUVmax and SUVmed) both in the primary tumour (T) as well as in axillary nodes (N) and whole-body (WB).
Forty females were included between January 2010-2011; follow up until January 2015 was completed. The average follow-up was 46 months. Twenty percent presented recurrence: local disease (n=2) and distant metastasis (n=6); 3 patients died (38% of the patients which recurred and 7.5% from the total). SUVmax, MTV and TLG, in T, N and WB, were higher in those patients with recurrence. The MTV and TLG parameters in the tumour (T) were related to the recurrence rate (P=.020 and P=.028, respectively); whereas SUVmax in the lymph nodes (N) was significantly related (P=.008) to the recurrence rate. The best cut-off points to predict recurrence where: MTV T ≥19.3cm, TLG T≥74.4g and SUVmax N≥13.8, being 10-12 times more likely to recidivate when these thresholds where exceeded. Tumour grade was the only clinical-pathological variable which was related to recurrence probability (p=.035).
In this study of LABC patients the metabolic parameters which have a better relationship with recurrence rate are: MTV and TLG in the primary tumour, SUVmax in the regional lymph node disease and whole-body PET data.
确定代谢肿瘤体积（MTV）和总病灶糖酵解（TLG）是否能够预测局部晚期乳腺癌（LABC）患者的复发风险。
对接受新辅助、局部和辅助治疗及随访的LABC患者进行回顾性研究。进行了一项F-FDG PET/CT初始分期研究，分析了原发肿瘤（T）、腋窝淋巴结（N）和全身（WB）的不同代谢参数（MTV、TLG、SUVmax和SUVmed）。
纳入了2010年1月至2011年期间的40名女性；随访至2015年1月结束。平均随访时间为46个月。20%的患者出现复发：局部疾病（n = 2）和远处转移（n = 6）；3例患者死亡（占复发患者的38%，占总患者的7.5%）。复发患者的T、N和WB中的SUVmax、MTV和TLG更高。肿瘤（T）中的MTV和TLG参数与复发率相关（分别为P = 0.020和P = 0.028）；而淋巴结（N）中的SUVmax与复发率显著相关（P = 0.008）。预测复发的最佳截断点为：MTV T≥19.3cm，TLG T≥74.4g，SUVmax N≥13.8，超过这些阈值时复发的可能性高出10至12倍。肿瘤分级是唯一与复发概率相关的临床病理变量（p = 0.035）。
在这项LABC患者研究中，与复发率关系更密切的代谢参数为：原发肿瘤中的MTV和TLG、区域淋巴结疾病中的SUVmax以及全身PET数据。
